Clinical Trial Update: Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating lenalidomide plus rituximab in patients with CD5+/CD20+ hematologic malignancies who relapse after rituximab, including mantle cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma

Drugs mentioned

• Revlimid (lenalidomide)
• Rituxan (rituximab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2014-09-01